期刊
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 70, 期 17, 页码 2128-2136出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2017.08.057
关键词
heart failure; LDLR; low-density lipoprotein receptor; PCSK9; proprotein convertase subtilisin/kexin type 9
资金
- European Commission [FP7-242209-BIOSTAT-CHF, EudraCT 2010-020808-29]
- Ministerio de Educacion y Ciencia [SAF2014-59892]
- Fundacio La MARATO de TV3 [201502, 201516]
- CIBER Cardiovascular [CB16/11/00403]
- AdvanceCat
- Novartis
- Roche Diagnostics
- Critical Diagnostics
- Abbott
- Rovi
- Vifor
- Alere
- Amgen
- Bayer
- Boehringer Ingelheim
- Cardio3Biosciences
- Celladon
- GlaxoSmithKline
- Merck/Merck Sharp Dohme
- Servier
- Stealth Peptides
- Singulex
- Sphingotec
- Trevena
- ZS Pharma
- Abbott Vascular
- Brahms
- Janssen
- ASTRA
- Astra Zeneca
- Merck Sharp Dohme
- Johnson Johnson
- National Institute for Health Research [NF-SI-0611-10227] Funding Source: researchfish
BACKGROUND Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds low-density lipoprotein receptor (LDLR), preventing its recycling. PCSK9 is a risk predictor and a biotarget in atherosclerosis progression. OBJECTIVES The aim of this study was to determine whether the PCSK9-LDLR axis could predict risk in patients with heart failure (HF). METHODS The BIOSTAT-CHF (Biology Study to Tailored Treatment in Chronic Heart Failure) is a multicenter, multinational, prospective, observational study that included patients with worsening HF signs and/or symptoms. The primary endpoints were all-cause mortality and the composite of mortality or unscheduled hospitalizations for HF. We implemented Cox proportional hazard regression to determine the simultaneously adjusted effect of PCSK9 and LDLR on both outcomes when added to the previously validated BIOSTAT-CHF risk scores. RESULTS This study included 2,174 patients (mean age: 68 +/- 12 years; 53.2% had a history of ischemic heart disease). Median (interquartile range) PCSK9 and LDLR levels were 1.81 U/ml (1.45 to 2.18) and 2.98 U/ml (2.45 to 3.53), respectively. During follow-up, 569 deaths (26.2%) and 896 (41.2%) composite endpoints were ascertained. A multivariable analysis, which included BIOSTAT-CHF risk scores, LDLR, and statin treatment as covariates, revealed a positive linear association between PCSK9 levels and the risk of mortality (hazard ratio [HR]: 1.24; 95% confidence interval [CI]: 1.04 to 1.49; p = 0.020) and the composite endpoint (HR: 1.21; 95% CI: 1.05 to 1.40; p = 0.010). A similar analysis for LDLR revealed a negative association with mortality (HR: 0.86; 95% CI: 0.76 to 0.98; p = 0.025) and the composite endpoint (HR: 0.92; 95% CI: 0.83 to 1.01; p = 0.087). Including PCSK9 and LDLR improved risk score performance. CONCLUSIONS The PCSK9-LDLR axis was associated with outcomes in patients with HF. Future studies must assess whether PCSK9 inhibition will result in better outcomes in HF. (C) 2017 by the American College of Cardiology Foundation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据